MetaCap

Oncolytics Biotech Inc. (ONCY)

NASDAQ: ONCYHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.3501-0.0405 (-10.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ONCY stock chart

Technical analysis

Key statistics

All statistics
Market cap
$47.66M
EPS (TTM)
-$0.33
52-week range
0.33 – 1.30
Day range
0.34 – 0.3885
Volume / Avg
1.11M / 1.17M
Beta
—

52-week range

$0.33$1.30

ONCY stock today

Shares of Oncolytics Biotech (ONCY) finished lower on Nov 20 at $0.3501, a drop of 10.37% or $0.0405 per share, versus the S&P 500's 3.70% decline. Shares are 73.1% below their 52-week high of $1.30, set on Jan 22, 2026 and 6.1% above the 52-week low of $0.33, near the bottom of the past year's range. ONCY is down 59.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 65.0%.

Oncolytics Biotech has posted a net loss over the last twelve months (EPS of -$0.33), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Oncolytics Biotech

Company profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Jared Kelly J.D., L.L.M.
Headquarters
San Diego, CA
Employees
29

Financial highlights

Full financials

Oncolytics Biotech reported a net loss of $28.8 million, compared with a loss of $22.8 million a year earlier. Diluted earnings per share came in at -$0.30.

Oncolytics Biotech annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2017FY 2016
Revenue——$6.18M$0
Growth————
Net income$-28.76M$-22.79M——
EPS (diluted)$-0.30$-0.30——

Analyst forecast

Forecast

Consensus (6 analysts)

buy

Avg. price target

$4.15+1085.38%

  • Strong buy 3
  • Buy 2
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $2.85High $5.86

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.08 vs $-0.07
Surprise
-14.29%

ONCY news

All ONCY news

Oncolytics Biotech peers

Health Care sector
ONCY peer companies
CompanyPrice% ChgMarket capCompare
RFLRafael Holdings Inc. Class B0.9197+2.19%$47.99Mvs ONCY
HRTXHeron Therapeutics Inc.0.2525-4.39%$48.04Mvs ONCY
NMADNomad Power Solutions Inc.2.56+13.53%$47.15Mvs ONCY
VRCAVerrica Pharmaceuticals Inc.2.74-5.03%$47.07Mvs ONCY
TNXPTonix Pharmaceuticals Holding Corp.2.38-6.67%$46.25Mvs ONCY
MISTMilestone Pharmaceuticals Inc.0.3711-7.06%$46.20Mvs ONCY
HOWLWerewolf Therapeutics Inc.0.9466-3.97%$46.00Mvs ONCY
ACRVAcrivon Therapeutics Inc.1.15-17.86%$49.35Mvs ONCY

Indexes, lists and sector

Oncolytics Biotech stock FAQ

What is Oncolytics Biotech's stock price today?

ONCY last traded at $0.3501 as of Nov 20, 4:00 PM EST, down 10.37% on the day. Prices are delayed at least 15 minutes.

Does Oncolytics Biotech pay a dividend?

No. Oncolytics Biotech does not currently pay a regular cash dividend.

Who is Oncolytics Biotech's CEO?

Mr. Jared Kelly J.D., L.L.M. is the chief executive officer of Oncolytics Biotech Inc., which has about 29 employees.

Has ONCY ever split its stock?

Yes. The most recent ONCY stock split was a 10-for-95 split on May 25, 2018.

What is the ONCY 52-week high?

The 52-week high for ONCY is $1.30 and the 52-week low is $0.33. The stock is currently 73.1% below its high.

Compare ONCY